Literature DB >> 15282768

The reproducible acquisition of comparative liquid chromatography/tandem mass spectrometry data from complex biological samples.

Ian I Stewart1, Li Zhao, Thierry Le Bihan, Brett Larsen, Salvatore Scozzaro, Dan Figeys, Guo Dong Mao, Olga Ornatsky, Moyez Dharsee, Chris Orsi, Rob Ewing, Theo Goh.   

Abstract

An in-depth study of the reproducibility of data acquired for comparative proteomics analysis using a prototype two-stage heated laminar flow chamber fitted to a commercial high-performance liquid chromatography/tandem mass spectrometry (HPLC/MS/MS) instrument was undertaken. The study is based on 24 replicate samples from four independent membrane preparations derived from two matched breast cancer cell lines. Variation and reproducibility in the data were evaluated at several levels highlighting the relative efficiency and variability of the acquisition routines used. Specifically, variation in the number and relative intensities of chromatographic peaks eluted from the LC column, precursor ion selection and sequence identification were evaluated. On average, approximately 6500 chromatographic peaks were generated for each acquisition with a corresponding coefficient of variance (CV) of less than 20%. Precursor ion selection and sequence identification averaged 1380 and 780 events per acquisition sample, respectively, with corresponding CVs of less than 10% for each. The reproducibility in the precursor ion selection was typically better than 60% between similar replicates. Using protein and peptide internal standards, it was found that the CV in retention time across the gradient between two acquisition pairs was typically less than 5%, whereas the average intensity ratio was 1.0 (expected) with a CV approaching 20%. An evaluation of the intensity ratios calculated from endogenous peptide sequences, identified across the acquisition set, indicated a CV of approximately 30%. Similarly, the CV associated with the top 1000 peptides indicated a mean and median of 28.4 and 26.95%. For a given acquisition pair it was also found that approximately 11% of the chromatographic peaks eluting from the column were linked to a sequence or identified. For these experiments, less than 10% of the peak pairs had absolute ratios greater than 2.0 and of those only approximately 10% had sequences linked to them. For each matched acquisition set on average 406 proteins were identified with a CV of less than 10%. Of the proteins that were identified approximately 30% had at least one predicted trans-membrane domain, indicating a four-fold increase over a crude homogenate sample with only minor enrichment. During these experiments it was found that the interface did not significantly alter the relative charge state distribution of ions, nor did it introduce significant interference from background ions. The interface was capable of 24-hour acquisition cycles.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15282768     DOI: 10.1002/rcm.1538

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  4 in total

1.  Stable gradient nanoflow LC-MS.

Authors:  Bradley B Schneider; Xu Guo; Lorne M Fell; Thomas R Covey
Journal:  J Am Soc Mass Spectrom       Date:  2005-09       Impact factor: 3.109

2.  Proteomic analysis of mitochondria in APOE transgenic mice and in response to an ischemic challenge.

Authors:  Rachel James; James L Searcy; Thierry Le Bihan; Sarah F Martin; Catherine M Gliddon; Joanne Povey; Ruth F Deighton; Lorraine E Kerr; James McCulloch; Karen Horsburgh
Journal:  J Cereb Blood Flow Metab       Date:  2011-08-31       Impact factor: 6.200

3.  Photobacterium profundum under pressure: a MS-based label-free quantitative proteomics study.

Authors:  Thierry Le Bihan; Joe Rayner; Marcia M Roy; Laura Spagnolo
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

4.  Current literature in mass spectrometry.

Authors: 
Journal:  J Mass Spectrom       Date:  2004-11       Impact factor: 1.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.